Quinnova announced the launch of Neosalus Cream, a non-steroidal anti-inflammatory cream for the treatment of various dermatoses (eg, atopic dermatitis, contact dermatitis, and hand eczema).

The FDA has approved a five-day dosing regimen for Dacogen (decitabine for injection, from Eisai) to treat patients with myelodysplastic syndromes (MDS).

The FDA has approved Trelstar 22.5mg (triptorelin pamoate for injectable suspension, from Watson) for the palliative treatment of advanced prostate cancer.

The FDA has approved Botox (onabotulinumtoxin A, from Allergan) for the treatment of spasticity in the flexor muscles of the elbow, wrist, and fingers in adults.

Arbor Pharmaceuticals announced the launch of Pediaderm HC Complete Kit which contains Pediaderm HC (hydrocortisone lotion 2%) and nonsteroidal Pediaderm Protective Emollient with Triple Synergy Technology.

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

The FDA has notified healthcare professionals and patients that at this point, the data that have been reviewed have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures.

Dainippon Sumitomo Pharma America announced that the FDA has accepted for filing the New Drug Application (NDA) submitted for lurasidone for the treatment of schizophrenia.

Antares Pharma announced that it has completed enrollment in the double-blind portion of their Phase 3 trial of Anturol (transdermal oxybutynin ATD gel) for the treatment of overactive bladder (OAB).

Bowel cleansing products used for colonoscopy preparation.

This schedule indicates the recommended age groups and medical indications for routine administration of currently licensed vaccines for persons 19 years and older.

A list of drugs used for the treatment of nausea. The chart includes the formulations, strengths, and usual doses for each antiemetic drug product.

A catch-up immunization schedule for children 4 months to 18 years of age. The tables show minimum intervals between doses for children who have delayed immunizations.

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines for children through age 18 years.